Rockefeller Capital Management L.P. lessened its stake in shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) by 24.4% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 23,250 shares of the biotechnology company’s stock after selling 7,500 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in Atara Biotherapeutics were worth $361,000 at the end of the most recent quarter.
Several other large investors also recently added to or reduced their stakes in the company. Arizona State Retirement System boosted its stake in shares of Atara Biotherapeutics by 5.0% during the first quarter. Arizona State Retirement System now owns 21,492 shares of the biotechnology company’s stock valued at $309,000 after purchasing an additional 1,020 shares during the period. Vontobel Holding Ltd. boosted its stake in shares of Atara Biotherapeutics by 11.1% during the first quarter. Vontobel Holding Ltd. now owns 20,000 shares of the biotechnology company’s stock valued at $287,000 after purchasing an additional 2,000 shares during the period. Geneos Wealth Management Inc. purchased a new stake in shares of Atara Biotherapeutics during the first quarter valued at approximately $30,000. Alliancebernstein L.P. boosted its stake in shares of Atara Biotherapeutics by 3.0% during the first quarter. Alliancebernstein L.P. now owns 81,140 shares of the biotechnology company’s stock valued at $1,165,000 after purchasing an additional 2,400 shares during the period. Finally, American International Group Inc. lifted its stake in Atara Biotherapeutics by 6.2% in the first quarter. American International Group Inc. now owns 46,732 shares of the biotechnology company’s stock worth $671,000 after acquiring an additional 2,733 shares during the period.
Separately, Zacks Investment Research lowered Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, Atara Biotherapeutics currently has a consensus rating of “Buy” and an average price target of $30.71.
Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Sunday, August 8th. The biotechnology company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.03). The firm had revenue of $3.87 million during the quarter, compared to analysts’ expectations of $6.32 million. On average, analysts expect that Atara Biotherapeutics, Inc. will post -3.64 EPS for the current year.
In related news, insider Joe Newell sold 10,500 shares of the stock in a transaction on Wednesday, September 22nd. The stock was sold at an average price of $17.00, for a total transaction of $178,500.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Pascal Touchon sold 8,223 shares of the stock in a transaction on Tuesday, August 17th. The shares were sold at an average price of $12.53, for a total value of $103,034.19. Following the sale, the chief executive officer now directly owns 336,891 shares in the company, valued at $4,221,244.23. The disclosure for this sale can be found here. Insiders have sold 32,460 shares of company stock worth $462,304 over the last ninety days. 3.80% of the stock is currently owned by insiders.
Atara Biotherapeutics Profile
Atara Biotherapeutics, Inc is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. also delivers off-the-shelf treatments to patients with high unmet medical need.
Read More: Death Cross
Want to see what other hedge funds are holding ATRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atara Biotherapeutics, Inc. (NASDAQ:ATRA).
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.